Home - Symmetron

Health economic modelling is a process for synthesising and comparing the costs and benefits of new (proposed) and existing medicines or devices in...

Learn more

Evidence generation and communication in drug development

Clinical evidence generation: clinical trials Health researchers continually discover new evidence that deepens our understanding of disease...

Learn more

Did you know that immuno-oncology therapies were more likely than other cancer therapies to be reimbursed by the Cancer Drugs Fund?

We have investigated this topic in our submission to ISPOR Europe 2021.

Learn More

🏅Our poster was ranked top 5% at ISPOR Europe 2021 🏅

The overall survival (OS) is the main efficacy outcome considered by HTA agencies, including NICE, when assessing immuno-oncology therapies. How can robust OS extrapolation aid reimbursement success?

Learn More

What does it take to secure reimbursement for new immuno-oncological treatments in the UK?

We have investigated this topic in our submission to ISPOR Europe 2021.

Learn More

What's the best value approach to treating drug-resistant epilepsy?

We have investigated this topic in our submission to ISPOR Europe 2021.

Learn More

How can patient-reported outcomes impact regulatory approval and reimbursement for new drugs?

We have investigated this topic in our submission to ISPOR Europe 2021.

Learn More

Economic value of insertable cardiac monitors in unexplained syncope in the United States

We’re excited to have co-authored a publication in the BMJ Open Heart Journal assessing the cost-effectiveness of a novel diagnostic device.

Learn More

Assessing the quality and coherence of network meta-analyses of biologics in plaque psoriasis: what does all this evidence synthesis tell us?

We’re thrilled to have co-authored a publication in Dermatology and Therapy to appraise and synthesise the published evidence on biological therapies for plaque psoriasis.

Learn More

Outcomes-based contracts for medicines in Europe

Are you interested in outcomes-based contracts? Click below to learn more about our work on European healthcare systems and challenges in planning and implementation.

Learn more

Vagus nerve stimulation for drug-resistant epilepsy patients in England

We’re excited to have published an economic evaluation of this innovative device.

Learn more

Our work in numbers

43

total clients

28

billion USD – average client turnover

67

% of work conducted with global HQ

Our story

We discover and drive innovative solutions to bring lifesaving treatments to patients around the world.

We work with our clients as a trusted partner and critical friend. Hence our name, Symmetron, from the Greek sym (together) and metron (calculate).

Since 2008, we have been growing steadily in size and capability into a highly-respected source of research in health economics and health outcomes.

Find out more about our successes.

We discover and drive innovative solutions to bring lifesaving treatments to patients around the world.

We work with our clients as a trusted partner and critical friend. Hence our name, Symmetron, from the Greek sym (together) and metron (calculate).

Since 2008, we have been growing steadily in size and capability to a highly-respected source of research in health economics and health outcomes.

Find out more about our successes.